2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
The primary objective is to test the feasibility (Study 1) and the effectiveness (Study 2) of using self-tracking device and web-based coaching platform to increase PA levels among patients in the early CR process. Effectiveness of the new approach…